Evidence map›Paper›PMID 30006243›Full record

ArticleToxicology and applied pharmacology2018

Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks.

Michal W Luczak, Anatoly Zhitkovich

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. MOF promotes cisplatin resistance in lung cancer cells by enhancing WSTF acetylation.In vitro cellular & developmental biology. Animal · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Monoubiquitination in Homeostasis and Cancer.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michal W LuczakDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI 02912, USA.
Anatoly ZhitkovichDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI 02912, USA. Electronic address: anatoly_zhitkovich@brown.edu.
Brown University · US

Funding

GENOTOXICITY OF CHROMIUM COMPOUNDSR01ES008786 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZHITKOVICH, ANATOLY · 1997 to 2019
$5.7M
Regulation of p53 and Checkpoint Signaling by Chromium(VI)R01ES028072 · NIEHS · BROWN UNIVERSITY · PI ZHITKOVICH, ANATOLY · 2018 to 2022
$1.8M
NIEHS NIH HHS R01 ES008786NIEHS NIH HHS R01 ES028072
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) are a highly toxic form of DNA damage produced by a number of carcinogens, drugs, and metabolic abnormalities. Involvement of DSBs in many pathologies has led to frequent measurements of these lesions, primarily via biodosimetry of S139-phosphorylated histone H2AX (γ-H2AX). However, γ-H2AX is also induced by some non-DSB conditions and abundantly formed in apoptosis, raising concerns about the overestimation of potential genotoxic agents and accuracy of DSB assessments. DSB-triggered γ-H2AX undergoes RNF168-mediated K13/K15 monoubiquitination, which is rarely analyzed in DSB/genotoxicity studies. Here we identified critical methodological factors that are necessary for the efficient detection of mono- (ub

Indexed as

ApoptosisBiomarkersCell LineChromatinDNA Breaks, Double-StrandedDNA ReplicationDNA Topoisomerases, Type IIDose-Response Relationship, DrugGene Knockdown TechniquesHeat-Shock ResponseHistonesHumansOxidative StressStem CellsUbiquitinationBiomarkersChromatinDNA Topoisomerases, Type IIH2AX protein, humanHistonesDNA damageDNA double-strand breakGenotoxicityHistone H2AXRNF168

Identifiers

PMID30006243
PMCPMC6754567
OpenAlexW2856225947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.